




# Guidelines for Global Surveillance of Drug Resistance in Leprosy



# Guidelines for Global Surveillance of Drug Resistance in Leprosy



**World Health  
Organization**

Regional Office for South-East Asia

© World Health Organization 2009

All rights reserved.

Requests for publications, or for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – can be obtained from Publishing and Sales, World Health Organization, Regional Office for South-East Asia, Indraprastha Estate, Mahatma Gandhi Marg, New Delhi 110 002, India (fax: +91 11 23370197; e-mail: [publications@searo.who.int](mailto:publications@searo.who.int)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

This publication does not necessarily represent the decisions or policies of the World Health Organization.

Printed in India

# Contents

	<i>Pages</i>
Foreword .....	v
1. Rationale .....	1
2. Objectives .....	2
2.1 General objective.....	2
2.2 Specific objectives.....	2
3. Surveillance methodology .....	3
4. Broad outline of the sentinel surveillance system .....	4
4.1 Anti-leprosy drugs to be investigated .....	4
4.2 Components .....	5
4.3 Selection of endemic countries .....	5
4.4 Documentation.....	5
5. Definitions and procedures .....	6
5.1 Relapse definition .....	6
5.2 Criteria for inclusion of MB relapse cases .....	6
5.3 Patient consent .....	7
5.4 At the referral facility.....	7
5.5 Information to be collected .....	7
6. Collection of samples and transportation.....	9
6.1 Molecular basis of rifampicin, dapsone and ofloxacin resistance and methods for detection .....	10
6.2 DNA extraction protocol.....	11
6.3 PCR protocol .....	12
6.4 DNA sequencing protocol.....	14



6.5	Reporting results of DNA sequencing .....	15
6.6	Quality control.....	15
6.7	Reference laboratories .....	16
7.	Laboratory tests.....	17
8.	Management of MB relapse cases included in the surveillance system.....	18
9.	Reporting and dissemination of information .....	19
10.	Conclusion .....	20

### **Annexes**

1.	Workflow of molecular detection for drug resistance in leprosy.....	21
2.	Form 1. Case Report Form( <i>MB Relapse cases only</i> ) .....	23
3.	Form 2. Reporting results of DNA sequencing .....	25
4.	Collaborating Reference Laboratories.....	27
5.	References.....	29

# Foreword

The emergence of drug resistance is a cause for concern and a threat for any infectious disease intervention programme. For leprosy, a chronic disease with social stigma, drug resistance poses a serious impediment especially at the stage where a dramatic decline in prevalence and new case detection has been achieved due to intensive and concerted chemotherapy interventions made by the national programmes and its global partners. There seems to be an extraordinary degree of complacency about drug resistance, in spite of current challenges faced by TB control programmes and the history of dapsone-resistance and its negative effects on the leprosy control strategies. This has resulted in lack of priority and absence of information on current magnitude of drug resistance in leprosy which, of course, is not evidence of an absence of drug resistance. It is assumed that a combination of three drugs, if taken regularly will prevent the emergence of drug resistance. In addition, there is limited information on patient adherence with the unsupervised components of multidrug therapy (MDT). Although the problem of drug resistance is presently not acute, it is important that we collect data more systematically and monitor the trend carefully so that effective measures to combat this problem can be developed. With the recent development of more practical and quick DNA sequencing methods to detect drug resistance, several reports of rifampicin, dapsone and ofloxacin resistance have been published which further highlights the emerging threat.

In order to contain the threat, WHO has planned the following two-pronged strategy:

- (1) To closely monitor trends in occurrence of relapses after treatment with MDT due to drug resistance, particularly to rifampicin, and
- (2) To promote research on developing new drugs for non-rifampicin containing regimens to limit and treat patients who relapse after completing one or more courses of MDT due to resistant strains of *M. leprae* (secondary resistance) and those new patients who are not responding to standard MDT regimen (primary resistance).

The establishment of a network for global surveillance of drug resistance in leprosy is primarily to keep a close vigil on the drug resistance scenario at many vulnerable settings. To accomplish this, WHO has developed a simple guidelines to carry out sentinel surveillance and this initiative is expected to be conducted annually on a routine basis. This initiative will be coordinated by WHO' Global Leprosy Programme with support and collaboration from national programmes and major research institutes around the world. The research institutes have offered to provide free-of-cost testing of samples sent to them from the sentinel sites in several endemic countries. The results will be published annually in the Weekly Epidemiological Record of WHO in agreement with the national programmes.

Dr. V. Pannikar  
Team Leader, Global Leprosy Programme  
World Health Organization

# Rationale 1

The emergence of drug resistance is a concern and a threat for many infectious disease intervention programmes especially when secondary prevention (chemotherapy) is the main component of the control strategy. The fight against leprosy has been a great success largely due to the development of multidrug therapy (MDT) in 1981. Since 1995, as a result of donations to WHO from The Nippon Foundation and Novartis Foundation for Sustainable Development all leprosy patients have had access to MDT free of cost. The effectiveness of MDT in curing leprosy in a short time has brought about a dramatic decrease in the disease burden in all leprosy-endemic countries. The disease prevalence has declined significantly especially in countries where leprosy has been highly endemic for decades and along with the decline in prevalence the annual new case detection has also started to decline in some countries.

Since rifampicin is the backbone of MDT, it is important to monitor the emergence of rifampicin-resistant mutants, as recent reports and

预览已结束，完整报告

<https://www.yunbaogao.cn/report/index>